Stocks To Watch: Intra-Cellular Therapies Sees Relative Strength Rating Rise To 93
Intra-Cellular Therapies had its Relative Strength (RS) Rating upgraded from 87 to 93 Tuesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This unique rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.